Distribution partnership expands access to RNA production tools

Europa Biosite has entered a strategic distribution partnership with Quantoom Biosciences, strengthening access to advanced mRNA technology platforms for researchers across Europe. The collaboration will make Quantoom’s RNA production solutions more widely available to academic, biotech and pharmaceutical laboratories working on next-generation vaccines and therapeutics.

As part of the agreement, Europa Biosite will distribute Quantoom’s Ntensify® mano and Ntensify® micro systems, designed to enable fast, high-quality RNA production in research environments. The partnership is also expected to expand in the future to include Ncapsulate® lipid nanoparticle (LNP) formulation kits as they become available for research use.

Europa Biosite, which operates a pan-European distribution network supplying life science technologies, continues to focus on strengthening its portfolio through partnerships with innovative suppliers. The addition of Quantoom’s RNA production suite further enhances its offering in a field experiencing rapid growth and increasing demand.

José Castillo, CEO of Quantoom Biosciences, said Europa Biosite has built a strong reputation for connecting innovative technologies with leading research laboratories across Europe. He added that the collaboration will help improve access to high-quality RNA production and formulation tools, supporting progress in RNA-based applications.

The companies aim to jointly support researchers by reducing technical barriers in RNA manufacturing and accelerating development workflows in therapeutic research.

Europa Biosite provides access to a broad range of research technologies through its coordinated European distribution network and continues to expand through strategic partnerships supported by EQT Healthcare Growth.

Quantoom Biosciences develops integrated RNA solutions for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox combines sequence design (Ncode), RNA production (Ntensify®) and LNP formulation (Ncapsulate®) into a connected workflow designed to support scalable development from antigen design to drug product.

More information online